Convalescence following surgery
Conditions
Interventions
Group A (ciprofol group):Anesthesia induction was performed using ciprofol injection 0.4mg/kg, and continuous infusion was given to the patient after they fell asleep. The starting dose was 0.8mg/kg/h
Group B (propofol group):Anesthesia induction was performed using propofol injection 2.0mg/kg, and continuous infusion was given to the patient after they fell asleep. The starting dose was 5mg/kg/h,
Sponsors
The Sixth Affiliated Hospital, South China University of Technology
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) The subjects have a full understanding of the purpose and significance of this trial, voluntarily participate in this clinical trial, and sign the informed consent; 2) Patients undergoing thoracoscopic thoracic surgery under general anesthesia; 3) Age 18-65 years old, gender is not limited; 4) 18 kg/m^2=BMI=30 kg/m^2; 5) American Society of Anesthesiologists (ASA) Grade I - III.
Exclusion criteria
Exclusion criteria: 1) People who are allergic to propofol, cyclopofol and other ingredients or components that may be used in the study; 2) Patients with long-term use of narcotic analgesics, sedatives or NSAIDs anti-inflammatory drugs; 3) Patients with systemic hypotension despite the use of vasoactive drugs; 4) Bradycardia, heart rate <55 beats/min; 5) High atrioventricular block without pacemaker; 6) Complicated with craniocerebral injury and intracranial hypertension; 7) Patients with severe heart, lung, liver and renal dysfunction; 8) Patients with a history of allergic disease, malignant hyperthermia in the past, and epilepsy in the past; 9) Subjects with a history of mental illness and cognitive dysfunction; 10) Fat metabolism disorders; 11) Predictable difficulty intubation; 12) Patients with myasthenia gravis; 13) Subjects with sensory disorders such as hyperalgesia; 14) History of alcoholism; 15) Have severe visual or hearing impairment; 16) Unable to cooperate to complete the test after surgery; 17) Other circumstances in which the investigator determines that the subject is not suitable to participate in the clinical trial; 18) Pregnant or lactating women; 19) HIV or RPR positive.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| QoR-15 score 24 hours after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| QoR-15 score 48 hours after surgery;Hemodynamic changes during induction;Intraoperative cerebral oxygen saturation;Postoperative recovery time; | — |
Countries
China
Contacts
Public ContactMo ping
The Sixth Affiliated Hospital, South China University of Technology
Outcome results
None listed